-

Aerin Medical Appoints Lucas Buchanan as Independent Board Director

MedTech veteran brings deep financial, strategic and commercial expertise

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the appointment of Lucas Buchanan to its Board of Directors. Mr. Buchanan will serve as an independent director, bringing important expertise and strategic perspective to guide Aerin’s significant value creation.

Mr. Buchanan brings more than 25 years of proven leadership in medical device commercialization, operations, and finance. Most recently he served as the Chief Operating Officer and Chief Financial Officer of Silk Road Medical, where he led the company from founding through its IPO in 2019, and then its $1.3 billion acquisition by Boston Scientific in 2024.

“We are thrilled to welcome Lucas to our Board of Directors at a significant time in Aerin’s growth,” said Matt Brokaw, President and CEO of Aerin Medical. “His experience and insights will be invaluable assets as we strengthen our market leadership foundation and work to change the standard of care for patients suffering from chronic ENT conditions.”

“Aerin Medical, in deep partnership with the ENT community, is improving the quality of life for individuals with nasal airway obstruction and chronic rhinitis, and I’m honored to join the company’s Board of Directors,” said Lucas Buchanan. “Throughout my career, I’ve aligned with organizations that combine standout innovation with compelling clinical evidence and meaningful patient impact, and I look forward to supporting this team’s mission-driven work.”

Mr. Buchanan also serves on the Board of Directors for Element Science, Inc., Endologix LLC, Procyrion, Inc., Route92 Medical, Inc., and as a strategic advisory board member of CRG LP, a healthcare focused investment fund. His background includes investing, finance and commercial roles at The Vertical Group, Impax Laboratories, Medtronic and Ernst & Young. He holds a BA in Economics from Duke University and an MBA in Health Care Management from The Wharton School at the University of Pennsylvania.

About Aerin Medical

Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin’s mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company’s products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 150,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.

Contacts

Media Contact:
Michael Fanucchi
Aerin Medical
mfanucchi@aerinmedical.com

Aerin Medical Inc.


Release Versions

Contacts

Media Contact:
Michael Fanucchi
Aerin Medical
mfanucchi@aerinmedical.com

More News From Aerin Medical Inc.

Aerin Medical Launches Next-Generation Device for Chronic Rhinitis Relief

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the launch of its next-generation RhinAer® device as well as UnitedHealthcare’s Medicare Advantage policy now covering RhinAer for treatment of the posterior nasal nerve (CPT 31242) effective immediately. The temperature- and impedance-controlled radiofrequency RhinAer+ device treats the posterior nasal nerve (PNN) and comprehensively targets multipl...

Three-Year Study Confirms Lasting Chronic Rhinitis Symptom Relief and Quality-of-Life Improvements with RhinAer®

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the publication of long-term results from a multicenter study evaluating the safety and efficacy of RhinAer, which uses temperature-controlled radiofrequency (TCRF) to target the posterior nasal nerve (PNN) in patients with chronic rhinitis (CR). Published in the American Journal of Rhinology & Allergy, the study followed patients for three years...

Cigna Enables Coverage for RhinAer®

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna’s list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patien...
Back to Newsroom